Turkiye Garanti Bankasi A.S.: Coupon payment of Subordinated Debt Securities to Qualified Investors

8 January 2021, 12:29 pm·4-min read

Turkiye Garanti Bankasi A.S. (TGBD) 08-Jan-2021 / 12:29 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. TO: Investment Community FROM : Garanti BBVA / Investor Relations SUBJECT: Coupon payment of Subordinated Debt Securities to Qualified Investors DATE: January 07, 2021 The fifth coupon payment of the subordinated Debt Securities that meet the criteria for the inclusion in Tier 2 Capital in the nominal value of TRY 252,880,000 with a maturity of 3651 days with 3 months coupon payments indexed to BIST TLREF index ; is done on 07.01.2021 . In contradiction between the Turkish and English versions of this public disclosure, the Turkish version shall prevail. We declare that our above statements are in conformity with the principles included in the Board's Communiqué, Serial II Nr.15.1, that it exactly reflects the information we received; that the information complies with our records, books and documents; that we did our best to obtain the correct and complete information relative to this subject and that we are responsible for the declarations made in this regard. Yours sincerely, Garanti BBVA Contact Garanti BBVA Investor Relations: Tel: +90 212 318 2352 Fax: +90 212 216 5902 E-mail: investorrelations@garantibbva.com.tr www.garantibbvainvestorrelations.com		Board Decision Date	30.07.2019	Related Issue Limit Info		Currency Unit	TRY	TRY	Limit	7,000,000,000	20.000.000.000	Issue Limit Security Type	Subordinated Debt Securities	Dept Securities	Sale Type	Sale To Qualified Investors	Public Offering-Sale To Qualified Investor	Domestic / Oversea	Domestic	Domestic	Capital Market Instrument To Be Issued Info		Type	Bond	Maturity Date	07.10.2029	Maturity (Day)	3651	Interest Rate Type	FRN	Sale Type	Sale To Qualified Investors	ISIN Code	TRSGRANE2915	Starting Date of Sale	03.10.2019	Ending Date of Sale	08.10.2019	Maturity Starting Date	09.10.2019	Nominal Value of Capital Market Instrument Sold	252,880,000	Coupon Number	40	Redemption Date	07.10.2029	Payment Date	08.10.2029	Was The Payment Made? No	No	Redemption Plan of Capital Market Instrument Sold	Coupon Number	Payment Date	Record Date	Payment Date	Interest Rate (%)	Interest Rate - Yearly Simple (%)	Interest Rate - Yearly Compound (%)	Payment Amount	Exchange Rate	Was The Payment Made?	1	07.01.2020	06.01.2020	07.01.2020	3,7162	9,397,526.56	Yes	2	07.04.2020	06.04.2020	07.04.2020	3,0351	7,675,160.88	Yes	3	07.07.2020	06.07.2020	07.07.2020	2,4533	6,203,905.04	Yes	4	07.10.2020	06.10.2020	07.10.2020	2,8171	7,123,882.48	Yes	5	07.01.2021	06.01.2021	07.01.2021	4,1584	10,515,761.92	Yes	6	07.04.2021	06.04.2021	07.04.2021	7	07.07.2021	06.07.2021	07.07.2021	8	07.10.2021	06.10.2021	07.10.2021	9	07.01.2022	06.01.2022	07.01.2022	10	07.04.2022	06.04.2022	07.04.2022	11	07.07.2022	06.07.2022	07.07.2022	12	07.10.2022	06.10.2022	07.10.2022	13	07.01.2023	06.01.2023	09.01.2023	14	07.04.2023	06.04.2023	07.04.2023	15	07.07.2023	06.07.2023	07.07.2023	16	07.10.2023	06.10.2023	09.10.2023	17	07.01.2024	05.01.2024	08.01.2024	18	07.04.2024	05.04.2024	08.04.2024	19	07.07.2024	05.07.2024	08.07.2024	20	07.10.2024	04.10.2024	07.10.2024	21	07.01.2025	06.01.2025	07.01.2025	22	07.04.2025	04.04.2025	07.04.2025	23	07.07.2025	04.07.2025	07.07.2025	24	07.10.2025	06.10.2025	07.10.2025	25	07.01.2026	06.01.2026	07.01.2026	26	07.04.2026	06.04.2026	07.04.2026	27	07.07.2026	06.07.2026	07.07.2026	28	07.10.2026	06.10.2026	07.10.2026	29	07.01.2027	06.01.2027	07.01.2027	30	07.04.2027	06.04.2027	07.04.2027	31	07.07.2027	06.07.2027	07.07.2027	32	07.10.2027	06.10.2027	07.10.2027	33	07.01.2028	06.01.2028	07.01.2028	34	07.04.2028	06.04.2028	07.04.2028	35	07.07.2028	06.07.2028	07.07.2028	36	07.10.2028	06.10.2028	09.10.2028	37	07.01.2029	05.01.2029	08.01.2029	38	07.04.2029	06.04.2029	09.04.2029	39	07.07.2029	06.07.2029	09.07.2029	40	07.10.2029	05.10.2029	08.10.2029	Principal/Maturity Date Payment Amount	07.10.2029	05.10.2029	08.10.2029	252,880,000
	Board Decision Date	30.07.2019
Board Decision Date	30.07.2019
Related Issue Limit Info
	Currency Unit	TRY	TRY	Limit	7,000,000,000	20.000.000.000	Issue Limit Security Type	Subordinated Debt Securities	Dept Securities	Sale Type	Sale To Qualified Investors	Public Offering-Sale To Qualified Investor	Domestic / Oversea	Domestic	Domestic
Currency Unit	TRY	TRY
Limit	7,000,000,000	20.000.000.000
Issue Limit Security Type	Subordinated Debt Securities	Dept Securities
Sale Type	Sale To Qualified Investors	Public Offering-Sale To Qualified Investor
Domestic / Oversea	Domestic	Domestic
Capital Market Instrument To Be Issued Info
	Type	Bond	Maturity Date	07.10.2029	Maturity (Day)	3651	Interest Rate Type	FRN	Sale Type	Sale To Qualified Investors	ISIN Code	TRSGRANE2915	Starting Date of Sale	03.10.2019	Ending Date of Sale	08.10.2019	Maturity Starting Date	09.10.2019	Nominal Value of Capital Market Instrument Sold	252,880,000	Coupon Number	40	Redemption Date	07.10.2029	Payment Date	08.10.2029
Type	Bond
Maturity Date	07.10.2029
Maturity (Day)	3651
Interest Rate Type	FRN
Sale Type	Sale To Qualified Investors
ISIN Code	TRSGRANE2915
Starting Date of Sale	03.10.2019
Ending Date of Sale	08.10.2019
Maturity Starting Date	09.10.2019
Nominal Value of Capital Market Instrument Sold	252,880,000
Coupon Number	40
Redemption Date	07.10.2029
Payment Date	08.10.2029
Was The Payment Made? No	No
Redemption Plan of Capital Market Instrument Sold
Coupon Number	Payment Date	Record Date	Payment Date	Interest Rate (%)	Interest Rate - Yearly Simple (%)	Interest Rate - Yearly Compound (%)	Payment Amount	Exchange Rate	Was The Payment Made?
1	07.01.2020	06.01.2020	07.01.2020	3,7162			9,397,526.56		Yes
2	07.04.2020	06.04.2020	07.04.2020	3,0351			7,675,160.88		Yes
3	07.07.2020	06.07.2020	07.07.2020	2,4533			6,203,905.04		Yes
4	07.10.2020	06.10.2020	07.10.2020	2,8171			7,123,882.48		Yes
5	07.01.2021	06.01.2021	07.01.2021	4,1584			10,515,761.92		Yes
6	07.04.2021	06.04.2021	07.04.2021
7	07.07.2021	06.07.2021	07.07.2021
8	07.10.2021	06.10.2021	07.10.2021
9	07.01.2022	06.01.2022	07.01.2022
10	07.04.2022	06.04.2022	07.04.2022
11	07.07.2022	06.07.2022	07.07.2022
12	07.10.2022	06.10.2022	07.10.2022
13	07.01.2023	06.01.2023	09.01.2023
14	07.04.2023	06.04.2023	07.04.2023
15	07.07.2023	06.07.2023	07.07.2023
16	07.10.2023	06.10.2023	09.10.2023
17	07.01.2024	05.01.2024	08.01.2024
18	07.04.2024	05.04.2024	08.04.2024
19	07.07.2024	05.07.2024	08.07.2024
20	07.10.2024	04.10.2024	07.10.2024
21	07.01.2025	06.01.2025	07.01.2025
22	07.04.2025	04.04.2025	07.04.2025
23	07.07.2025	04.07.2025	07.07.2025
24	07.10.2025	06.10.2025	07.10.2025
25	07.01.2026	06.01.2026	07.01.2026
26	07.04.2026	06.04.2026	07.04.2026
27	07.07.2026	06.07.2026	07.07.2026
28	07.10.2026	06.10.2026	07.10.2026
29	07.01.2027	06.01.2027	07.01.2027
30	07.04.2027	06.04.2027	07.04.2027
31	07.07.2027	06.07.2027	07.07.2027
32	07.10.2027	06.10.2027	07.10.2027
33	07.01.2028	06.01.2028	07.01.2028
34	07.04.2028	06.04.2028	07.04.2028
35	07.07.2028	06.07.2028	07.07.2028
36	07.10.2028	06.10.2028	09.10.2028
37	07.01.2029	05.01.2029	08.01.2029
38	07.04.2029	06.04.2029	09.04.2029
39	07.07.2029	06.07.2029	09.07.2029
40	07.10.2029	05.10.2029	08.10.2029
Principal/Maturity Date Payment Amount	07.10.2029	05.10.2029	08.10.2029				252,880,000


ISIN:	US9001487019
Category Code:	MSCL
TIDM:	TGBD
Sequence No.:	91099
EQS News ID:	1159358


End of Announcement	EQS News Service

Yahoo Finance UK
DAVOS 2021: Santander CEO says vaccines are the most effective economic policy
Ana Botin said EU and ECB stimulus had been key in 2020, but vaccines would be central for European economies in 2021.
a few seconds ago
Reuters
Analysis: Chinese majors to struggle to extend shale gas boom beyond 2025
Chinese oil majors will struggle to extend fast growth in shale gas production beyond 2025, as complex geology and failure to draw in more investors make it expensive to develop the unconventional resource. That would be a blow to China's efforts to cut its reliance on gas imports, presently 42% of total consumption. It would also mean Beijing will have to step up development of other costly gas resources in its remote northwest to meet demand, as the country steers away from coal to achieve climate goals.
2 minutes ago
Evening Standard
Best ovens 2021: Top built-in electric, gas and mini oven alternatives
An investment item - it’s important to get it right
2 minutes ago
PA Media: UK News
Vaccine minister reveals uncle died of Covid-19
Nadhim Zahawi was speaking on Good Morning Britain.
4 minutes ago
Evening Standard
Afternoon naps help boost memory and mental agility, study finds
‘In addition to reducing sleepiness, mid-day naps offer a variety of benefits’
4 minutes ago
Globe Newswire
Global Oncology Bispecific CD3 Molecules Analytical Tool 2021: 67 Companies Plus Partners who are Today Developing 148 Drugs, 127 are in Active Development in Cancer Across 63 Different Targets
Dublin, Jan. 26, 2021 (GLOBE NEWSWIRE) -- The "Bispecific CD3 Molecules in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. There is a considerable and robust commercial drug pipeline of T-cell redirecting therapies by bispecific compounds that targets various tumor antigens expressed by malignant cells, and CD3 expressed by the T-cell. Upon binding to both targets, these compounds redirect T-cell cytotoxicity toward the malignant cells and effectively eradicate them.Bispecific CD3 Molecules in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of immune-oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your bispecific CD3 drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.Keeping you "In the know"Simply put, our mission is to fuel your knowledge of immune-oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. Your Bispecific CD3 Molecules in Oncology: Analytical Tool covers more than 67 companies plus partners who are today developing 148 bispecific CD3 drugs where of 127 are in active development in cancer across 63 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.Let our expertise work for youWith a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.Your key to access development at the world-leading cancer meetingsThe Bispecific CD3 Molecules in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.Run combination therapy analysis like no otherThe Bispecific CD3 Molecules in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.Unparalleled biomarker surveillanceWe also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.Support and inspiration at your finger-tipsYou also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.A tool to grow with and keep you informedUnlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.Bispecific CD3 Molecules in Oncology: Analytical Tool achieves this by continuously scanning development in bispecific CD3 and reporting: Deals & CollaborationsNew technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)Funding/Grants/IPOsFilings & ApprovalsLatest Clinical Trial Development & ResultsNewly launched clinical trialsConference Coverage of the world's twelve leading meetings in oncologyQuarterly & Annual Reporting This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today! Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as: Emerging TechnologiesTarget NoveltyRecent FundingEarly & Late Stage PipelineBiomarker/Companion Diagnostic Development (featured below)Entered Deals & AlliancesConference surveillance of world leading cancer meetings (featured below)Combination Therapy Choices (featured below)Outcome of Clinical TrialsIndication Selection & Expansion ChoicesDrug Repositioning Opportunities For more information about this report visit https://www.researchandmarkets.com/r/3pm5fw Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
4 minutes ago
Evening Standard
Haute Couture Week makes a strong case for bonkers ear bling
From eye-catch evil eyes to discussion-diverting golden molars, now’s a great time to invest in some wonderfully wacky ear armoury, says Chloe Street
4 minutes ago
Globe Newswire
HSBC BANK PLC - Form 8.5 (EPT/RI) - TalkTalk Telecom Group plc
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree TalkTalk Telecom Group plc (c) Name of the party to the offer with which exempt principal trader is connected: Offeree - TalkTalk Telecom Group plc (d) Date dealing undertaken: 25 January 2021 (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” N/A 2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received (GBP) Lowest price per unit paid/received (GBP) Ordinary Shares Purchase 400 97.220 p 97.220 p Ordinary Shares Sale 400 97.220 p 97.220 p (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (GBP) (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 3. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” Date of disclosure: 26 January 2021 Contact name: Mukhtar Khan Telephone number: 0207 088 2000 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
5 minutes ago
Business Wire
Global Conveyor Systems Industry (2020 to 2025) - Need for Secure Environment in Industries Drives Large Scale Installation of Conveyor Systems - ResearchAndMarkets.com
The "Conveyor Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
6 minutes ago
The Guardian
Football transfer rumours: Real Madrid to move for Kylian Mbappé?
Football transfer rumours: Real Madrid to move for Kylian Mbappé?Today’s fluff is spinning plates, and dropping most of them
6 minutes ago
Evening Standard
Wycombe boss Gareth Ainsworth still keen on Jose Mourinho collaboration: ‘I bet he plays a mean tambourine!’
Wycombe boss Gareth Ainsworth says he was “humbled” to share a touchline with Jose Mourinho in last night’s FA Cup defeat to Tottenham and joked the Portuguese could play a “mean tambourine” in his band. The Championship side were knocked out of the competition after a 4-1 defeat, but only after they had given the Premier League side a real scare, taking a first-half lead and then remaining on terms after Gareth Bale’s equaliser until the 86th-minute, before a flurry of late goals put some gloss on the scoreline. As well as managing Wycombe, Ainsworth is the lead singer in a rock band called Cold Blooded hearts.
7 minutes ago
Globe Newswire
Global $612 Billion Red Phosphor Market Analysis and Forecast to 2025: Business Opportunities in Increasing Rates of Mining & Targeting Chinese and Southeast Asian Markets
Dublin, Jan. 26, 2021 (GLOBE NEWSWIRE) -- The "Global Red Phosphor Market - A Global and Regional Analysis: Focus on Product Types and Their Applications, and Countries - Analysis and Forecast, 2020-2025" report has been added to ResearchAndMarkets.com's offering. The global red phosphor market accounted for $476.16 billion in 2019 and is expected to reach $612.52 billion by 2025. The market is anticipated to grow at a CAGR of 4.56% during the forecast period 2020 -2025. The global red phosphor market's growth is mainly attributed to the increased demand for matchsticks, flame retardants, semiconductors, and fertilizers in multiple application areas such as automotive, agriculture, and pyrotechnics. Additionally, the implementation of government laws and regulations across the globe limits the production and import of red phosphor. This discourages the demand for red phosphor on a global scale. The increasing emphasis on advanced and innovative technologies and products in the red phosphor industry creates several opportunities for the manufacturers to expand their revenue stream and product portfolios by using the 6N and 7N type red phosphorous in the semiconductor and electronics sector for developing and manufacturing innovative products. The market growth is mainly attributed to the rising number of applications for red phosphor, increasing adoption and awareness rates, and heavy investments made in the research and development of red phosphor-based end-use products and solutions in the industry and its development. In addition, governments are coming up with policies and laws to encourage the import of red phosphorous in a transparent manner, which is expected to drive market growth during the forecast period. COVID-19 has hit the red phosphor industry hard in terms of import of raw -material, transportation, and maintenance of a smooth supply/demand. The unavailability of sufficient raw material has created an imbalance in supply for medium-scale manufacturers as well as small-scale and medium-scale end users. Competitive Landscape Earlier, the applications of red phosphor were limited to matchsticks and fertilizers, but the innovation and development of red phosphor-based electronics such as semiconductors and transistors boost the capabilities of red phosphor in the mentioned industries. The red phosphor manufactured currently has significantly higher shock resistance as compared to its alternatives such as white, black, or yellow phosphorus. Continuous product expansions (launches and enhancements) are some of the business strategies executed in the red phosphor market. Several companies, including BASF SE, Clariant AG, Nippon Chemical Industrial Co., Ltd, and Wylton (China) Chemicals Co., Ltd. have been involved in product launches and enhancements. Key Questions Answered in this Report: What was the revenue generated by the global red phosphor market in 2019, and what is the revenue expected to be generated by the market by 2025?What are the major market drivers, challenges, and opportunities in the global red phosphor market?How is the global red phosphor market expected to grow during the forecast period based on the segments? The segments are: ElectronicsChemicalAgriculturalMetallurgicalOthers (Pyrotechnics and Explosives) What are the key development strategies implemented by the major players in order to sustain in the competitive market?What are the key regulatory implications in developed and developing regions for red phosphor?Which are the leading players with significant offerings to the global red phosphor market? What is the current market dominance for each of these leading players? Key Topics Covered: 1 Markets1.1 Industry Outlook1.1.1 Trends: Current and Future1.1.1.1 Rising Country Trades of Red Phosphor1.1.1.2 Increasing Demand for Red Phosphor as Fertilizers1.1.2 Supply Chain Network1.1.3 Industry Attractiveness1.2 Business Dynamics1.2.1 Business Drivers1.2.1.1 High Recovery and Recycle Rate1.2.1.2 Rising Demand for Semiconductors1.2.1.3 Advancements in Agriculture Through Red Phosphor1.2.2 Business Challenges1.2.2.1 Stringent Government Laws Regarding In-House Production1.2.2.2 Less Reactivity Than White Phosphorus1.2.3 Business Strategies1.2.3.1 Product Developments1.2.3.2 Market Development1.2.4 Business Opportunities1.2.4.1 Increasing Rates of Mining1.2.4.2 Targeting Chinese and Southeast Asian Markets 2 Application2.1 Global Red Phosphor Market - Applications and Specifications2.1.1 Electronics2.1.2 Chemical2.1.3 Agriculture2.1.4 Metallurgy2.1.5 Others2.2 Global Red Phosphor Market - Demand Analysis (by Application)2.2.1 Demand Analysis (by Application Type), Value and Volume Data, 2019-2025 3 Products3.1 Global Red Phosphor Market - Products and Specifications3.1.1 General Purity3.1.2 High Purity3.2 Global Red Phosphor Market - Demand Analysis (by Product)3.2.1 Demand Analysis (by Product), Value and Volume Data, 2019-2025 4 Region4.1 North America4.1.1 Market4.1.1.1 Key Manufacturers and Suppliers in North America4.1.1.2 Competitive Benchmarking4.1.1.3 Business Challenges4.1.1.4 Business Drivers4.1.2 Application4.1.3 Product4.1.4 North America: Country-Level Analysis4.2 South America4.3 Europe4.4 U.K.4.5 Middle East and Africa (MEA)4.6 China4.7 Asia-Pacific and Japan (APJ) 5 Markets - Competitive Benchmarking & Company Profiles BASF SECelestin Petroleum Co. LtdChangzhou Junlin Chemical Co., Ltd.Clariant AGGuangzhou Chemicals Co., LtdJinding Group Co., LTDNippon Chemical Industrial Co., Ltd.Prasol Chemicals Private LimitedRasa Industries Ltd.RIN KAGAKU KOGYO Co., Ltd.Smart-elements GmbHSpectrum Chemical Mfg. Corp.Taj Pharmaceuticals LimitedUPL Ltd.Wylton (China) Chemical Co., Ltd. For more information about this report visit https://www.researchandmarkets.com/r/xez254 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
9 minutes ago
HuffPost
Chris Cuomo Pays Tribute To Larry King: A Big Reason Why I’m In Your Face Tonight
King's death was "another reason to hate COVID," said the CNN anchor who remembered the broadcasting legend's impact on his own career.
10 minutes ago
Evening Standard
Piers Morgan responds to calls for him to become Prime Minister: Could I do any worse?
Piers Morgan has responded to calls for him to become Prime Minister, suggesting he “couldn’t do any worse” than Boris Johnson. The calls follow a string of gruelling political interviews by Morgan, 55, where the journalist has put various MPs on the spot for their apparent failures in office. On Monday, Secretary of State for Work and Pensions Thérèse Coffey turned off her video call camera following a difficult interview with Morgan.
10 minutes ago
Reuters
Sterling hits 1-week low vs dollar as risk sentiment pulls back
Sterling fell to its lowest in a week against the dollar and traded near one-week lows against the euro on Tuesday as more subdued risk sentiment across broader asset markets weighed on the currency. Expectations of a large U.S. fiscal stimulus package from U.S. President Joe Biden's administration has fuelled risk sentiment in markets in recent weeks, benefiting the pound, which has hit 2-1/2 year highs against a weakened dollar. Sterling has also hit its highest against the euro since May 2020 last week, with analysts attributing the pound's gains to a slower COVID-19 vaccine rollout in the European Union than in Britain.
11 minutes ago
PA Media: UK News
Quarantine hotels set to be introduced to limit spread of coronavirus variants
Vaccines Minister Nadhim Zahawi said an announcement on the plans would be made later.
12 minutes ago
Bloomberg
Kuaishou to Give Asian IPOs Best Start to a Year Since 2010
(Bloomberg) -- The world’s biggest internet initial public offering since Uber Technologies Inc. is set to make this the best start to a year for stock listings in Asia since 2010.Kuaishou Technology’s Hong Kong IPO of as much as $5.4 billion will push the amount raised through first-time share sales in the region in 2021 to $9.93 billion, the most for a January month in 11 years, data compiled by Bloomberg show. Almost $11 billion was raised in January 2010.The bumper start comes against a backdrop of ebullient regional markets that continue to hit records amid a flood of liquidity from central banks trying to stave off the economic damage from the coronavirus pandemic.The continuing boom in Asia share listings follows on from the trend seen last year globally, where investors piled into offerings in search for returns, sending company valuations soaring on their debuts. Globally, IPOs are having their best start to the year on record, driven predominantly by listings in the U.S. which account for 85% of proceeds worldwide, Bloomberg-compiled data show.Blank check companies are continuing their fundraising spree from last year, with almost $24 billion raised in the U.S. so far. That represents 66% of the money fetched from first-time share sales globally. The blank check IPOs are spreading to Asia too, with many eyeing assets in the region.The latest was a $260 million IPO by Bridgetown 2 Holdings Ltd., a special purpose acquisition company backed by billionaires Richard Li and Peter Thiel, that is targeting businesses in the technology, financial services or media sectors in Southeast Asia.Kuaishou, the operator of China’s most popular video service after ByteDance Ltd.’s Douyin, appears to have picked the right time to go public. The Tencent Holdings Ltd.-backed startup will stop taking orders from institutional investors two days earlier than planned, a sign of very strong investor demand. It has already reserved around 45% of the shares it is offering for high-profile cornerstone investors.Earlier IPOs have also proved popular with investors, particularly mom and pop buyers. Health-care technology company Yidu Tech Inc. soared 148% on its debut this month after retail investors put in orders for 1,634 times the shares initially made available to them.(Updates with data on global IPOs in fourth, fifth paragraphs)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
12 minutes ago
Variety
Fox Picks Up Canadian Legal Drama ‘Diggstown’ From Entertainment One
Fox has picked up Canadian legal drama “Diggstown” from Entertainment One. Created by Floyd Kane, and starring Vinessa Antoine (“General Hospital,” “Being Erica”), the series from Canadian public broadcaster CBC follows Marcie Diggs (Antoine), a star corporate lawyer who reconsiders her priorities and moves to work in a legal-aid office after her aunt commits suicide […]
12 minutes ago
The Guardian
Covid in the UK: how first cases exposed flaws in response
Covid in the UK: how first cases exposed flaws in responseHandling of earliest cases early last year provided ominous foretaste of things to come * Timeline of the first Covid cases in the UK * Coronavirus – latest updates * See all our coronavirus coverage
12 minutes ago
PA Media: Money
Unemployment rate soars to highest level for more than four years
The Office for National Statistics revealed the jobless rate reached 5% for the first time since early 2016 in the three months to November.
13 minutes ago

FTSE 100

FTSE 250

AIM

GBP/EUR

GBP/USD

BTC-GBP

CMC Crypto 200

S&P 500

DOW

CRUDE OIL

GOLD FUTURES

NIKKEI 225

HANG SENG

DAX

CAC 40

UK government warned 'little appetite' for ditching workers' rights as MPs vote

TO: Investment Community

FROM : Garanti BBVA / Investor Relations

Fax: +90 212 216 5902

E-mail: investorrelations@garantibbva.com.tr

Latest stories